These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3124027)

  • 1. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
    Tariska I; Gallai M
    Orv Hetil; 1983 Sep; 124(38):2309-14. PubMed ID: 6415577
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
    Przuntek H; Kuhn W
    J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deprenyl and the progression of Parkinson's disease.
    Science; 1990 Jul; 249(4966):303-4. PubMed ID: 2115691
    [No Abstract]   [Full Text] [Related]  

  • 6. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
    Trebini F; Daniele D; Gillio S; Scarzella L
    Acta Neurol (Napoli); 1985 Oct; 7(5):432-9. PubMed ID: 3933283
    [No Abstract]   [Full Text] [Related]  

  • 8. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 11. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-(-)-deprenyl in the treatment of end-of-dose akinesia.
    Ulm G; Fornadi F
    J Neural Transm Suppl; 1987; 25():163-72. PubMed ID: 3123603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
    Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
    J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experiences with L-deprenyl in Parkinsonism.
    Csanda E; Antal J; Antóny M; Csanaky A
    J Neural Transm; 1978; 43(3-4):263-9. PubMed ID: 370348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of L-deprenyl in Parkinson's disease].
    Zhonghua Yi Xue Za Zhi; 1983 Mar; 63(3):147-9. PubMed ID: 6409375
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism.
    Fischer PA; Baas H
    J Neural Transm Suppl; 1987; 25():137-47. PubMed ID: 3123600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.